GalNAc-ANGPTL4 siRNA

N/A

Report date: 2025/06/11 10:48:48
NME

Base Information

Drug NameGalNAc-ANGPTL4 siRNA
Drug Alias NameANGPTL4 gene-silencing siRNA therapy (Leaderna Therapeutics)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionAngiopoietin-related protein 4 inhibitors
TargetsAngiopoietin-related protein 4
Therapy Area/IndicationsLipid Metabolism DisordersNutritional and Metabolic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesLeaderna Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLeaderna Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsLipid Metabolism Disorders
Inactive IndicationsNutritional and Metabolic Diseases

Other Information

ATC CodeN/A
Related LinksN/A